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One Sentence Summary: The bioactive lipid 5-oxoETE is specifically increased in 40 
constipation predominant irritable bowel syndrome and mediates nociception through a novel 41 
MAS-related G protein coupled receptor D (Mrgprd) pathway.  42 
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Abstract 43 
 Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by 44 
chronic abdominal pain concurrent with altered bowel habit. Polyunsaturated fatty acid (PUFA) 45 
metabolites such as prostaglandin E2 (PGE2) are elevated in IBS and implicated in visceral 46 
hypersensitivity. The aim of this study was to quantify PUFA metabolites in IBS patients and 47 
evaluate their role in pain. Quantification of PUFA metabolites by mass spectrometry in colonic 48 
biopsies showed an increase in 5-oxo-eicosatetraenoic acid (5-oxoETE) only in biopsies taken 49 
from IBS with predominant constipation (IBS-C) patients. Local 5-oxoETE administration 50 
induced somatic and visceral hypersensitivity with no tissue inflammation. 5-oxoETE directly 51 
acts on both human and mouse sensory neurons as shown by lumbar splanchnic nerve 52 
recordings and Ca2+-imaging of dorsal root ganglia (DRG) neurons. 5-oxoETE selectively 53 
stimulated isolectin B4 (IB4)-positive DRG neurons through a PLC and pertussis toxin-54 
dependent mechanism, suggesting a G-protein coupled receptor-mediated effect. The MAS-55 
related G protein coupled receptor D (Mrgprd) was found in mouse colonic DRG afferents and 56 
was identified as the target receptor for 5-oxoETE. In conclusion, 5-oxoETE, a potential 57 
biomarker of IBS-C, activates Mrgprd in nociceptors and induces somatic and visceral 58 
hyperalgesia without inflammation. Thus, 5-oxoETE may play a pivotal role in abdominal pain 59 
associated with IBS-C.  60 
  61 
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Introduction 62 
 IBS is a functional bowel disorder in which recurrent abdominal pain is associated with 63 
a change in bowel habit, typically constipation (IBS-C), diarrhea (IBS-D), or a mixed 64 
(constipation and diarrhea) bowel habit (IBS-M) (1). IBS is a common disorder in Western 65 
populations affecting around 11% of the global population (2), with a higher prevalence in 66 
women than men (1). Although the aetiology of IBS remains unclear, low-grade inflammation 67 
has been widely described in this disorder, with several fundamental studies implicating pro-68 
inflammatory molecules in the pathophysiology of IBS symptoms (3). We have previously 69 
shown that the levels of several PUFA metabolites, also defined as bioactive lipids, are 70 
significantly altered in biopsy samples from IBS patients compared to controls (4). This is in 71 
agreement with previous studies focused on the prostanoid subtype of PUFA metabolites (5-7).  72 
The functional relationship between PUFAs and pain has been the subject of many 73 
studies (8). Both basic and clinical studies have revealed that a dietary intake of n-3 series 74 
PUFAs results in a reduction in pain associated with rheumatoid arthritis (9, 10), dysmenorrhea 75 
(11), inflammatory bowel disease (12), and neuropathy (13), while n-6 series PUFAs are high 76 
in patients with chronic pain including IBS patients (4, 14, 15). N-3 PUFA metabolites such as 77 
resolvins (Rv) are analgesic in multiple pain models, an effect attributed to inhibition of certain 78 
transient receptor potential (TRP) channels (16). For example, RvE1 has been shown to 79 
specifically inhibit TRPV1 signaling (17), while RvD1 attenuates the function of TRPA1 and 80 
TRPV4 (18) and RvD2 inhibits TRPV1 and TRPA1 activity (19). These effects have been 81 
observed with other types of n-3 PUFAs such as maresin 1 (Mar1), which also has inhibitory 82 
effects on TRPV1 channel function (20) and reduces pain. The quantification of Rvs in knee 83 
synovia of patients suffering from inflammatory arthritis suggests that synthesis of specialized 84 
pro-resolving mediators (SPM) at the site of inflammation may be a mechanism of endogenous 85 
pain relief in humans. In contrast, n-6 PUFA metabolites have been shown to be pro-nociceptive 86 
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by stimulating nerve fibers via the activation of immune cells (21, 22). Nonetheless, several n-87 
6 PUFA metabolites such as thromboxane A2 (TXA2), PGE2, leukotriene B4 (LtB4) and PGD2, 88 
can directly stimulate sensory nerve fibers (23-26). Although, some n-6 PUFA metabolites, 89 
such as lipoxins, can inhibit pain (27). Consistent with the role of TRP channels in the 90 
transduction of noxious stimuli, we have previously shown a robust correlation between PUFA 91 
metabolites and TRP channel activation, particularly for the TRPV4 agonist 5,6-92 
epoxyeicosatrienoic acid (5,6-EET) and pain intensity in IBS-D patients (4). Interestingly, 93 
PUFA metabolites from colonic biopsies of IBS-C patients induced Ca2+ influx in sensory 94 
neurons independently of TRPV4, suggesting that the PUFA metabolites produced in IBS-C 95 
and IBS-D are distinct (4). Thus, the aim of this study was to identify algogenic PUFA 96 
metabolites specifically produced in IBS-C patients and decipher the mechanism by which they 97 
may activate sensory nerves. Herein, we show that 5-oxoETE, an n-6 PUFA subtype selectively 98 
increased in colonic tissues from IBS-C patients, induces hypersensitivity through Mrgprd 99 
activation. 100 
 101 
 102 
  103 
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Results 104 
5-oxoETE is increased in colonic biopsies from IBS-C patients 105 
PUFA metabolites were quantified in colonic biopsies from IBS patients and healthy controls 106 
(HC) using liquid chromatography/tandem mass spectrometry (LC-MS/MS). Hierarchical 107 
clustering of PUFA metabolite amounts quantified in biopsies (pg/mg of protein) was used to 108 
reveal the main differences between HC, IBS-M, IBS-C and IBS-D patients (Fig.1A). PUFA 109 
metabolites formed 5 different clusters. The first cluster contained products of arachidonic acid 110 
metabolism (PGE2, TXB2, 5,6-EET and 14,15-EET), eicosapentaenoic acid metabolism (18-111 
HEPE, LtB5 and PGE3) and PDx. This first cluster of metabolites was higher in biopsies from 112 
IBS-D patients (Fig.1A). Of note, TxB2, PGE2 and 5,6-EET were only increased in biopsies of 113 
IBS-D patients (Fig. S1). By contrast, TxB2 was decreased in biopsies from IBS-C patients (Fig. 114 
S1). The second cluster discriminated only 5-oxoETE, which was significantly elevated in 115 
biopsies from IBS-C patients (Fig.1A and 1B). The concentration of 7-MaR1 and 15dPGJ2, 116 
delineated a third cluster, which although presenting a trend towards increasing levels, did not 117 
reach statistical significance in biopsies from any group of IBS patients (Fig. S2). The fourth 118 
cluster, grouping the majority of lipoxygenase-derived metabolites, was decreased in biopsies 119 
from all subtypes of IBS patients (Fig.1A). 15-, 5-, 12-HETE and 14-, 17-HDoHE were 120 
significantly decreased in all IBS patients (Fig. S2). In addition, 12-HETE was significantly 121 
decreased in biopsies from IBS-C patients (Fig. S1). The metabolites included in the fifth cluster 122 
were reduced only in biopsies from IBS-C and IBS–D (Fig.1A). RvD1 and RvD2 were not 123 
detectable in any colonic biopsies.  124 
 Thus, amongst all PUFA metabolites quantified in colonic biopsies from IBS patients, 125 
5-oxoETE was the only one to be significantly upregulated in IBS-C patients compared to the 126 
other IBS subtypes (Fig.1B) and thus warranted further investigation.  127 
 128 
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Local administration of 5-oxoETE induces somatic and visceral hyperalgesia without 129 
inflammation 130 
As PUFA metabolites can stimulate the immune system and/or directly stimulate nerves, 131 
we first assessed the effect of 5-oxoETE on pain and inflammation processes in vivo. In a first 132 
set of experiments, 5-oxoETE was subcutaneously injected into the paw of mice and the paw-133 
withdrawal threshold to mechanical stimuli was estimated using calibrated von Frey filaments. 134 
The time course of mechanical hypersensitivity of the mice receiving 5-oxoETE was compared 135 
with that of mice injected with vehicle (HBSS). Basal mechanical sensitivity, measured in the 136 
paw before injection, was identical in both groups of mice (Fig.2A). Injection of 5-oxoETE into 137 
hind paws resulted in a decrease of the paw-withdrawal threshold (Fig.2A) and was observed 138 
from 15 min up to 2 hours after 5-oxoETE injection, with a peak reduction at 30 min. The 139 
mechanical pain threshold was decreased in a dose-dependent manner 30 min after 5-oxoETE 140 
administration with an EC50 of 0.6 µM (Fig.2B). In addition, paw edema formation and 141 
histological analysis were investigated to verify whether injection of 5-oxoETE induced an 142 
inflammatory process or not. Injection of 5-oxoETE into the hind paw did not induce paw 143 
edema (Fig. S3). Moreover, histological analysis of paw tissue did not reveal any sign of 144 
inflammation. Likewise, neither tissue disruption nor cellular infiltration was observed even 6 145 
hours after injection of 100 µM of 5-oxoETE (Fig.2C). Thus, at the somatic level, 5-oxoETE 146 
increased paw sensitivity to mechanical stimulation without inducing quantifiable 147 
inflammatory reaction. 148 
 Intracolonic administration of 5-oxoETE resulted in an increased intensity of abdominal 149 
contractions in response to colorectal distension (Fig.2D). Moreover, the increased intensity of 150 
abdominal contractions was observed in response to both innocuous (allodynia) and noxious 151 
(hyperalgesia) stimuli 30 min after 5-oxoETE treatment (Fig.2D). Intracolonic treatment with 152 
vehicle (40% ethanol) did not alter abdominal contraction response (Fig.2D). As observed 153 
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following subcutaneous hind paw injection, intracolonic administration of 5-oxoETE did not 154 
induce inflammation of the colon. Colonic inflammation was assessed by macroscopic scoring 155 
and myeloperoxidase activity, which were not increased by 5-oxoETE administration when 156 
compared to vehicle (Fig. S3). Moreover, histological analysis did not reveal intestinal wall 157 
thickening, leukocyte infiltration into the lamina propria, presence of ulceration or goblet cell 158 
depletion (Fig.2E).  159 
Thus, in vivo local administration of 5-oxoETE induces visceral hyperalgesia in the 160 
absence of inflammation, thus suggesting a direct effect on nociceptors. 161 
 162 
5-oxoETE stimulates visceral and somatic nociceptors: translation to human DRG 163 
 To confirm a direct effect of 5-oxoETE on sensory nerves, we examined its effects upon 164 
nerve discharge in mouse colonic nociceptors. Application of 100 µM of 5-oxoETE induced an 165 
axonal discharge in 38% of lumbar splanchnic (colonic) nerve fibers assessed (Fig.3). In a 166 
second set of experiments, we determined the effect of 5-oxoETE on Ca2+ mobilization in 167 
primary cultures of neurons from mouse DRG. In preliminary experiments performed with a 168 
working solution containing Ca2+ and Mg2+, we observed a transient increase in [Ca2+]i (data 169 
not shown). To determine if this transient increase was the consequence of intracellular Ca2+ 170 
release or influx of external Ca2+, experiments were performed without Ca2+ and Mg2+ in the 171 
extracellular solution. Even without Ca2+ in the extracellular compartment, 5-oxoETE evoked 172 
a transient increase in [Ca2+]i that was maximal after 10–20 seconds and declined to baseline 173 
afterwards (Fig.4A). The mobilization of intracellular Ca2+ by 5-oxoETE treatment was 174 
concentration-dependent (Fig.4B). Similarly, 5-oxoETE also induced an increase in [Ca2+]i and 175 
the percentage of responding neurons in a concentration-dependent manner in human primary 176 
sensory neurons (Fig.4C).  177 
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Thus, our data indicate that 5-oxoETE directly activates colonic DRG neurons from 178 
mice, as well as human sensory neurons, inducing an increase in [Ca2+]i (Fig.4) and nociceptor 179 
firing (Fig.3).  180 
 As 5-oxoETE induces somatic pain without inflammation in vivo, we hypothesised that 181 
5-oxoETE predominantly activates IB4+ sensory neurons, which do not release neuropeptides 182 
involved in neurogenic inflammation. To assess our hypothesis, mouse sensory neurons were 183 
labelled with isolectin B4 and treated with 10 µM 5-oxoETE without Ca2+ in the extracellular 184 
medium. 5-oxoETE induced an increase in [Ca2+]i in more than 50% of IB4-positive neurons, 185 
but not in IB4-negative neurons (Fig.4D). To decipher the intracellular pathway responsible for 186 
the intracellular Ca2+ mobilization by 5-oxoETE, sensory neurons were pretreated with 187 
pertussis toxin (PTX, a Gi, G protein inhibitor) or the PLC inhibitor U73122. In neurons 188 
pretreated with the pertussis toxin (PTX; 250 ng/ml), the increase in [Ca2+]i induced by 5-189 
oxoETE was significantly decreased (Fig.4E). Pre-treatment of sensory neurons with U73122 190 
(10µM) also inhibited the increase in [Ca2+]i induced by 5-oxoETE (Fig.4E).  191 
Thus, 5-oxoETE directly stimulates IB4-positive sensory neurons via a Gi/o/Gq-192 
coupled, G-protein-coupled receptor.  193 
 194 
5-oxoETE activates sensory neurons and induces visceral hypersensitivity via Mrgprd 195 
 Due to 5-oxoETE specifically activating IB4+ sensory neurons via Gi-protein-196 
mediated signalling pathways, we focused our attention on the MAS-related G protein receptor 197 
D (Mrgprd), which is Gi/o/Gq coupled. The expression and function of Mrgprd in polymodal 198 
nociceptors innervating the skin is well established (28), however for visceral tissues this 199 
remains less clear. In order to comprehensively assess this, we retrogradely labelled sensory 200 
afferents from the colon using microinjection of Fast Blue (FB) in wild-type mice and 201 
MrgprdEGFP-tagged mice. Single-cell qRT-PCR was performed on FB-expressing cells from 202 
9 
 
the dorsal root ganglia from wild-type mice. Mrgprd mRNA was detected at some level in 40% 203 
(18/45) of FB-labelled sensory neurons projecting to the colon via the splanchnic nerve 204 
originating from thoracolumbar (T10-L1) DRG (Fig.5A). Trpv1 mRNA was observed in 82% 205 
(37/45) of cells, with 41% (15/37) of Trpv1-positive neurons also expressing Mrgprd mRNA 206 
(Fig.5A). Immunohistochemistry was performed on the T13 DRG from the MrgprdEGFP-tagged 207 
mice to determine the incidence of GFP-expression and the peptidergic marker calcitonin gene 208 
related peptide (CGRP) in FB-labelled cells, revealing two distinct non-overlapping 209 
populations (Fig.5B). In agreement with previous studies, those sensory neurons labelled from 210 
the colon with the retrograde tracer Fast-Blue were predominantly CGRP-positive (~70%). By 211 
contrast, GFP immunoreactivity was observed in a restricted subset of colonic sensory neurons, 212 
accounting for only 7% of FB-labelled cells (Fig. 5B and Table 2). Of the 274 FB+ cells 213 
assessed, only cell one co-expressed both Mrgprd and CGRP. Those neurons projecting to the 214 
viscera represent ~10% of the total population of T10-L1 DRG neurons. Thus, only a very small 215 
population (between less than 1% and 4%) of T10-L1 DRG neurons are likely to be both colon 216 
projecting and Mrgprd-positive. 217 
In experiments using an antibody against Mrgprd, we observed, infrequent yet 218 
reproducible, co-localisation of Mrgprd with PGP9.5 in the colon of 6 wild-type mice out of 10 219 
assessed (Fig.S4). Importantly, Mrgprd immunoreactivity was not observed in the colon of 220 
Mrgprd-deficient mice (Fig.S4). The expression of Mrgprd was also assessed in human sensory 221 
neurons. As shown in Fig.5C, Mrgprd immunoreactivity was present in 22% of human T11 222 
DRG neurons, which also co-expressed the pan-neuronal marker PGP9.5. In a culture of human 223 
sensory neurons, 20% of PGP9.5-positive neurons possessed Mrgprd immunoreactivity 224 
(Fig.5D).  225 
 To demonstrate the role of Mrgprd in 5-oxoETE-induced neuronal firing, its expression 226 
was silenced by transducing primary cultures of mouse sensory DRG neurons with a 227 
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recombinant lentivirus expressing a shRNA directed against Mrgprd and the gene reporter red 228 
fluorescent protein (RFP). As a control, neurons were transduced with a lentivirus expressing a 229 
scrambled shRNA. As expected, the percentage of neurons responding to 5-oxoETE was 230 
significantly reduced in sensory neurons expressing shRNA against Mrgprd compared to those 231 
neurons expressing the scrambled shRNA (Fig.6A). Accordingly, application of 5-oxoETE on 232 
sensory neurons from Mrgprd-deficient mice had no greater effect than HBSS alone (Fig.6B). 233 
In contrast, treatment of Mrgprd-deficient sensory neurons with a mix of GPCR agonists 234 
(bradykinin, serotonin and histamine, 10 µM each), used as a positive control, induced an 235 
increase in [Ca2+]i (Fig.6B). Reciprocally, 5-oxoETE induced a concentration-dependent 236 
increase in [Ca2+]i only in Mrgprd-transfected CHO cells (Fig.6C). In a last set of experiments, 237 
the sensitivity to colorectal distension was assessed in Mrgprd-deficient mice 30 min after 238 
intracolonic administration of 5-oxoETE (10 µM). In contrasting to wild-type mice, 5-oxoETE 239 
did not induce hypersensitivity in response to colorectal distension in Mrgprd-deficient mice 240 
(Fig.6D). 241 
  242 
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Discussion  243 
 Our results show that: 1) Concentrations of the PUFA metabolite 5-oxoETE are 244 
significantly increased in biopsies from patients with IBS-C compared to other IBS subtypes 245 
and healthy controls; 2) 5-oxoETE induces somatic, as well as visceral hyperalgesia, without 246 
promoting inflammation; 3) 5-oxoETE activates both mouse and human sensory neurons; 4) In 247 
mouse, 5-oxoETE signals through Mrgprd. Taken together, these data clearly highlight a role 248 
for 5-oxoETE and Mrgprd-expressing IB4-positive sensory neurons in visceral hypersensitivity 249 
in IBS-C patients. 250 
 Eicosanoids and docosanoids are the most important lipids implicated in inflammatory 251 
processes; they derive from the oxidation of twenty and twenty-two carbon PUFA, respectively 252 
(29). Several PUFA metabolites increased in the intestinal mucosa from patients with 253 
inflammatory bowel diseases such as TXA2, PGE2, LTB4 or PGD2 induce visceral afferent fiber 254 
activation (23-26). Here, we show that PGE2, 5,6-EET and TXB2 are significantly increased in 255 
the intestinal mucosa of IBS-D patients while no alteration of PUFA metabolism was observed 256 
in IBS-M.  Interestingly, if lipid extracts from controls and all IBS patients are compared, a 257 
significant decrease in 14-HDoHE and 17-HDoHE which are precursors of specialized pro-258 
resolving mediators (SPM) (30), is observed. As SPM possess an analgesic effect (31), the pain 259 
associated with IBS could be also the consequence of a decrease in SPM leading to sensory 260 
neuron activation. A complete characterization of the different SPM produced by EPA, DHA 261 
or DPA metabolism will be of interest for the characterization of bioactive lipids potentially 262 
linked with pain in IBS patients. 263 
 We show that the concentration of 5-oxoETE only increases in colonic biopsies of IBS-264 
C patients highlighting its potential relevance as a new marker of the disease. 5-oxoETE, which 265 
derives from arachidonic acid (AA) metabolism, is produced by a variety of inflammatory cells. 266 
Additionally, it can also be synthesized from 5-HETE by stromal cells, possibly by transcellular 267 
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biosynthesis (32). 5-oxoETE is formed by the oxidation of 5-HETE by 5-hydroxyeicosanoid 268 
dehydrogenase (5-HEDH) (33), a microsomal enzyme that is highly selective for 5S-HETE and 269 
requires NADP+ as a cofactor (34). 5-HEDH is found in neutrophils as well as in a variety of 270 
other inflammatory and stromal cells, including monocytes (35), dendritic cells (36) and 271 
intestinal epithelial cells (37). 5-oxoETE has been widely shown to be a potent chemoattractant 272 
for human and rat eosinophils and to indirectly promote the survival of these cells (38). 273 
Nevertheless, no cellular infiltration was observed either in the paw or intestinal mucosa of 274 
mice administered with 5-oxoETE. This discrepancy may be due to the rapid metabolism of 5-275 
oxoETE in vivo (32) or the absence of other molecules such as interleukin-5 acting in synergy 276 
to attract inflammatory cells during inflammatory processes or allergies (39). In our 277 
experiments, the injection of 5-oxoETE alone, without cofactors, could thus explain the absence 278 
of infiltration by polymorphonuclear cells. Formation of 5-oxoETE needs NADP+ (40). 279 
Accordingly, oxidative stress associated with IBS-C (41) may improve the conversion rate of 280 
NADPH into NADP+ in epithelial cells, thereby resulting in the synthesis of larger amounts of 281 
5-oxoETE. 282 
 In a previous study, we reported that PUFA metabolites extracted from biopsies of IBS-283 
C and IBS-D patients triggered an increase in [Ca2+]i in primary sensory neurons, while those 284 
of IBS-M had no effect (4). We further identified the PUFA metabolite 5,6-EET as a TRPV4 285 
agonist with algogenic activity, specifically associated with IBS-D sub-group (4). By contrast, 286 
no PUFA metabolite with TRP agonist activity was found to be increased in IBS-C patient 287 
biopsies (4). Since only 5-oxoETE is increased in biopsies of IBS-C patients, we hypothesized 288 
that this PUFA metabolite may be responsible for the activation of sensory neurons and 289 
hypersensitivity-associated with IBS-C. As previously reported in humans, 5-oxoETE may 290 
interact with OXE receptor. However, there is no homologous OXE receptor in rodents (40). 291 
Since the observed 5-oxoETE-induced increase in [Ca2+]i in mouse sensory neurons was 292 
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inhibited by both PLC inhibitor and pertussis toxin (PTX), we hypothesized that 5-oxoETE 293 
binds to Gi/o/Gq protein-coupled receptors. Given that 5-oxoETE acts selectively on IB4+ 294 
sensory neurons, the targeted receptor should be specifically expressed on this neuronal 295 
subclass. Accordingly, we investigated the role of MAS-related G protein coupled receptor D 296 
(Mrgprd), a receptor specifically expressed on IB4+ sensory neurons, which may be coupled to 297 
Gq protein and to PTX–sensitive Gi/o proteins (42), previously reported as a key player in 298 
mechanical hypersensitivity (43-45).  299 
Stimulation of Mrgprd positive neurons with -alanine, the prototypical agonist of 300 
Mrgprd, increased [Ca2+]i, as observed here after 5-oxoETE treatment (46). Moreover, in a 301 
FLIPR (Fluorescent Imaging Plate Reader) assay developed for the simultaneous identification 302 
of Mrgprd agonists and antagonists, a PLC inhibitor completely blocked the FLIPR response 303 
to -alanine while PTX treatment resulted in 50% reduction in [Ca2+] (47). Again, similar 304 
results were obtained here by using PTX or PLC inhibitor to inhibit 5-oxoETE-induced 305 
activation of primary mouse sensory neurons. Using tissue from adult MrgprdEGFP mice stained 306 
with antibodies to GFP, a previous study showed that Mrgprd is expressed in non-peptidergic 307 
neurons that innervate the epidermis, but failed to observe Mrgprd-positive fibres in any other 308 
visceral organs including both the small and large intestine (28). By contrast, numerous studies 309 
using different retrograde tracers have identified a minor population (20-26%) of IB4+ sensory 310 
neurons that innervate the colon (48-50). Indeed, a recent study also identified Mrgprd mRNA 311 
in colonic sensory neurons by single cell RNA-sequencing (51). In order to confirm the 312 
presence of both Mrgprd mRNA and Mrgprd protein expression in colonic sensory neurons in 313 
the present study, we applied a similar retrograde neurotracing approach using single cell RT-314 
qPCR and anti-GFP immunostaining in MrgprdEGFP mice. We observed Mrgprd mRNA and 315 
Mrgprd protein expression in sensory DRG neurons projecting to the colon at similar frequency 316 
to that observed in previous studies (51), thereby not only confirming the presence of a Mrgprd-317 
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positive colonic neuronal subtype, but also reinforcing Mrgprd as a potential target of 5-318 
oxoETE. The activity of 5-oxoETE towards Mrgprd was attested to by its ability to induce an 319 
increase in [Ca2+]i in IB4-positive sensory neurons, but not in lentivirus-mediated Mrgprd 320 
knocked-down or Mrgprd-deficient mouse neurons. Conversely, while Ca2+ transients were 321 
triggered in CHO cells transfected with a Mrgprd-expression plasmid, CHO cells transfected 322 
with a control plasmid were not responsive to 5-oxoETE. 323 
Activation of Mrgprd inhibits a fraction of the total M-current, carried primarily by the 324 
KCNQ2/3 K+ channel, contributing to an increase in excitability of DRG neurons (52). Thus, 325 
Mrgprd activation by 5-oxoETE might promote the excitability of primary nociceptive afferents 326 
by KCNQ inhibition. Several groups have demonstrated that retigabine, a KCNQ2–5 opener, 327 
is effective in reducing neuropathic (53) and inflammatory pain (54). At the visceral level, 328 
retigabine reduces capsaicin-induced visceral pain and can inhibit noxious chemosensitivity in 329 
human tissue indicating that KCNQ channels play an inhibitory role in the transmission of 330 
visceral nociception (55, 56). Given that human sensory DRG neurons express Mrgprd and are 331 
activated by 5-oxoETE, we may assume that 5-oxoETE modulates KCNQ channels via Mrgprd 332 
activation leading to neuronal activation contributing to pain symptoms associated with IBS-C. 333 
Nevertheless, as OXER1 is expressed in human tissue, we cannot exclude an activation of this 334 
receptor by 5-oxoETE in human tissue. Taken together, our results strengthen previous findings 335 
from our laboratory showing a pivotal role of PUFA metabolites in visceral pain associated 336 
with IBS (4). Specifically, our study identifies 5-oxoETE with pro-nociceptive activity, as a 337 
hallmark of IBS-C subtype.  338 
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Materials and methods 339 
Chemicals  340 
6-keto-prostaglandin F1 (6kPGF1), thromboxane B2 (TXB2), prostaglandin E2 (PGE2), 341 
prostaglandin A1 (PGA1), 8-iso prostaglandin A2 (8-iso PGA2), prostaglandin E3 (PGE3), 15-342 
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), lipoxin A4 (LxA4), lipoxin B4 (LxB4), lipoxin A4 343 
deuterated (LxA4-d5), resolvin D1 (RvD1), resolvin D2 (RvD2), 7-maresin (7-MaR1), 344 
leukotriene B4 (LTB4), leukotriene B5 (LTB5), leukotriene B4 deuterated (LTB4-d4), 345 
10(S),17(S)-protectin (PDx), 18-hydroxyeicosapentaenoic acid (18-HEPE), dihydroxy-346 
eicosatetraenoic acid (5,6-DiHETE), 15-hydroxyeicosatetraenoic acid (15-HETE) and 12-347 
HETE, 8-HETE, 5-HETE, 5-HETE-d8, 17-hydroxy-docosahexaenoic acid (17-HDoHE) and 348 
14-HDoHE, 14,15-epoxyeicosatrienoic acid (14,15-EET) and 11,12-EET, 8,9-EET, 5,6- EET, 349 
5-oxoeicosatetraenoic acid (5-oxoETE) were purchased from Cayman Chemicals (Ann Arbor, 350 
MI, USA). 351 
 352 
Patients 353 
Patients (Table 1) were recruited from outpatient clinics of the Department of Medical and 354 
Surgical Sciences of the University of Bologna (Italy), and were included according to Rome 355 
III criteria for IBS. Healthy controls (HC) were asymptomatic subjects undergoing colonoscopy 356 
for colorectal cancer screening. In this group, we excluded subjects based on the presence of 357 
the following symptoms in the last 12 months: abdominal discomfort or pain, bloating, and 358 
bowel habit changes. Exclusion criteria for both IBS and HC included major abdominal surgery, 359 
any organic syndrome, celiac disease (excluded by detection of anti-transglutaminase and anti-360 
endomysial antibodies), asthma, food allergy, or other allergic disorders. None of these patients 361 
or HC were taking nonsteroidal anti-inflammatory drugs or any other anti-inflammatory drugs 362 
(including steroids, antihistamines, and mast cell stabilizers). Patients and HC gave written 363 
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informed consent. The study protocol was approved by the local Ethic Committee 364 
(64/2004/O/Sper and EM14/2006/O) and conducted in accordance with the Declaration of 365 
Helsinki. Patients underwent colonoscopy and, in all cases, 6 mucosal biopsies were obtained 366 
from the proximal descending colon. One biopsy was sent to the pathology department for 367 
exclusion of microscopic colitis or other microscopic tissue abnormalities and 4 were used in 368 
other studies. One biopsy was snap-frozen in liquid nitrogen for lipid extraction and PUFA 369 
quantification for the purpose of our study. 370 
 371 
Lipid extraction 372 
Biopsies were crushed with a FastPrep®-24 Instrument (MP Biomedicals, Illkirch, France) in 373 
500 µL of Hank's balanced salt solution (HBSS, Invitrogen, Villebon sur Yvette, France) and 5 374 
µL of internal standard mixture (LxA4-d5, LTB4-d4 and 5-HETE-d8 at 400 ng/mL in MeOH). 375 
After 2 crush cycles (6.5 m/s, 30 s), 10 µL were withdrawn for protein quantification and 300 376 
µL of cold methanol were added. Samples were centrifuged at 1000 g for 15 min at 4 °C. 377 
Supernatants were collected, completed to 2 mL in H2O and submitted to solid-phase extraction 378 
using HRX-50 mg 96-well (Macherey Nagel, Hoerd, France). Briefly, after plate conditioning, 379 
the sample was loaded at flow rate of 0.1 mL/min. After complete loading, the plate was washed 380 
with H2O/MeOH (90:10, 2 mL) and lipid mediators were eluted with MeOH (2 mL). Solvent 381 
was evaporated under nitrogen and samples were dissolved with MeOH and stored at -80 °C 382 
for liquid chromatography/tandem mass spectrometry measurements. 383 
 384 
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) measurements 385 
6kPGF1, TXB2, PGE2, PGA1, 8-isoPGA2, PGE3, 15d-PGJ2, LxA4, LxB4, RvD1, RvD2, 7-386 
MaR1, LTB4, LTB5, PDx, 18-HEPE, 5,6-DiHETE, 15-HETE, 12-HETE, 8-HETE, 5-HETE, 387 
17-HDoHE, 14-HDoHE, 14,15-EET, 11,12-EET, 8,9-EET, 5,6-EET and 5-oxo-ETE were 388 
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quantified in human biopsies (57). To simultaneously separate 28 lipids of interest and 3 389 
deuterated internal standards, LC-MS/MS analysis was performed on ultra high performance 390 
liquid chromatography system (UHPLC, Agilent LC1290 Infinity) coupled to Agilent 6460 391 
triple quadrupole MS (Agilent Technologies) equipped with electro-spray ionization operating 392 
in negative mode. Reverse-phase UHPLC was performed using ZorBAX SB-C18 column 393 
(Agilent Technologies) with a gradient elution. The mobile phases consisted of water, 394 
acetonitrile (ACN) and formic acid (FA) (75:25:0.1; v/v/v) (A) and ACN, FA (100:0.1, v/v) 395 
(B). The linear gradient was as follows: 0% B at 0 min, 85% B at 8.5 min, 100% B at 9.5 min, 396 
100% B at 10.5 min and 0% B at 12 min. The flow rate was 0.35 mL/min. The autosampler was 397 
set at 5 °C and the injection volume was 5 µL. Data were acquired in Multiple Reaction 398 
Monitoring (MRM) mode with optimized conditions. Peak detection, integration and 399 
quantitative analysis were done using Mass Hunter Quantitative analysis software (Agilent 400 
Technologies). For each standard, calibration curves were built using 10 solutions at 401 
concentrations ranging from 0.95 ng/mL to 500 ng/mL. A linear regression with a weight factor 402 
of 1/X was applied for each compound. The limit of detection (LOD) and the limit of 403 
quantification (LOQ) were determined for the 28 compounds using signal to noise ratio (S/N). 404 
The LOD corresponded to the lowest concentration leading to a signal to noise over 3 and LOQ 405 
corresponded to the lowest concentration leading to a signal to noise over 10. All values under 406 
the LOQ were not considered. Blank samples were evaluated, and their injection showed no 407 
interference (no peak detected), during the analysis. Hierarchical clustering and heat-map were 408 
obtained with R (www.r-project.org). PUFA metabolite amounts were transformed to z-scores 409 
and clustered based on 1-Pearson correlation coefficient as distance and the Ward algorithm as 410 
agglomeration criterion. 411 
 412 
 413 
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Animals 414 
C57BL/6 male mice (3 weeks-old) were purchased from Janvier (Le Genest Saint Isle, France). 415 
Mrgprdcre/+ mice were a generous gift from Dr D. Anderson at Caltech Pasadena. These mice 416 
were previously generated by Rau et al 2009 (44) and were in an almost pure C57/Bl6J 417 
background when we received them at IBDM (Institut de Biologie du Développement de 418 
Marseille) mouse facility. There, the mice were kept as heterozygous and were backcrossed to 419 
C57/Bl6J for another 8 generations. Mrgprd deficient mice used in this study were obtained by 420 
intercrossing Mrgprdcre/+ heterozygous mice. Animals were maintained in ventilated cages (4 421 
mice per cage) in a specific pathogen free room at 20–24 °C and relative humidity (40%–70%) 422 
with a 12 hours light/dark cycle and given free access to food and water. Animal Care and ethic 423 
Committee of US006/CREFE (CEEA-122) approved the whole study protocol (permit No. 424 
MP/01/64/09/12). MrgprdEGFP-tagged mice (B6;129SP2-Mrgprdtm4.1(COP4)Mjz/Mmnc; MMRRC, 425 
North Carolina, USA) were raised and maintained at the University of Glasgow, and have been 426 
characterised previously (58). Experiments conducted at the University of Glasgow were 427 
approved by the University’s Ethical Review Process Applications Panel, and were performed 428 
in accordance with the European Community directive 86/609/EC and the United Kingdom 429 
Animals (Scientific Procedures) Act 1986. 430 
 431 
Measurement of somatic nociception 432 
Paw-withdrawal thresholds were measured using calibrated von Frey filaments with forces 433 
ranging from 0.04 to 2 g (Stoelting, Wood Dale, IL, USA), which were applied onto the plantar 434 
surface of mice. Ascending series of von Frey filaments were applied with each monofilament 435 
being tested 5 times for approximately 1 second. Threshold to mechanical stimuli was 436 
calculated as the force value of the von Frey filament triggering 3 paw withdrawals over 5 437 
applications (59). Responses to mechanical stimuli were recorded before and 15 min, 30 min, 438 
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1 hour, 2 hours and 6 hours after an intraplantar injection of 0.1, 1, 10 or 100 µM of 5-oxoETE 439 
or its vehicle (HBSS). In a second set of experiments, paw edema was measured using digital 440 
calipers (resolution 0.01; Mitutoyo, Aurora, IL, USA) at 1, 2, 3 and 4 hours after intraplantar 441 
injection of 100 µM of 5-oxoETE. At the end of the experiment, paws were collected for 442 
histological analysis by hematoxylin and eosin staining (H&E). 443 
 444 
Colorectal distension (CRD) and electromyography recordings 445 
Mice were administered either 100 μL of 5-oxoETE (10 µM) or its vehicle (40% ethanol) 446 
intracolonically. We performed a session of CRD and recorded visceromotor responses (VMR) 447 
from implanted electrodes before and 30 min after treatment as previously described (60). Data 448 
are presented as the difference between the VMR induced by the distension performed before 449 
and after intracolonic treatments. After distension, mouse colons were harvested to perform 450 
histological analysis (H&E) and myeloperoxidase activity assay.  451 
 452 
Lumbar splanchnic nerve recording 453 
The distal colon with associated lumbar splanchnic nerves was removed from male C57BL/6 454 
mice (12 weeks). The colon was then opened along the anti-mesenteric border and pinned flat 455 
mucosal side up. The tissue was perfused (7 mL/min; 32-34 ℃) with carbogenated Krebs buffer 456 
(in mM: 124 NaCl; 4.8 KCl; 1.3 NaH2PO4; 2.4 CaCl2; 1.2 MgSO4.7H2O; 11.1 glucose; 25 457 
NaHCO3) and supplemented with 10 µM nifedipine and 10 µM atropine to block smooth 458 
muscle contraction, and 3 µM indomethacin to inhibit endogenous prostanoid production. 459 
Single unit activity was discriminated using wave form analysis software (Spike 2 Cambridge 460 
Electronic Design) from fibers teased from the lumbar splanchnic nerve (rostral to the inferior 461 
mesenteric ganglia), recorded using borosilicate glass suction electrodes. Signals were 462 
amplified, band pass filtered (gain 5K; 100-1300 Hz; Neurology, Digitiser Ltd, UK), digitally 463 
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filtered for 50Hz noise (Humbug, Quest Scientific, Canada), digitalised at 20 kHz (micro1401; 464 
Cambridge Electronic Design, UK) and displayed on a computer using Spike 2 software. 465 
Individual receptive fields of afferent nerve fibers were identified by systematically probing the 466 
tissue with a 1 g von Frey filament. Receptive fields that responded to probing and not to stretch 467 
were identified as serosal units (61). Once a serosal unit was identified a metal ring was placed 468 
over the receptive field and the baseline activity was observed for 3 min. The Krebs solution 469 
within the ring was then removed and replaced by 100 µM 5-oxoETE pre-warmed to bath 470 
temperature. Following a 7 min challenge period the 5-oxoETE and ring were removed. 471 
 472 
Immunofluorescence in mouse colon 473 
The descending colons of 10 wild-type and 10 Mrgprd deficient mouse were cryoprotected in 474 
OCT compound, sectioned at a thickness of 10 µm (one every 0.1 cm, 20 per mouse) on a 475 
cryostat (Leica CM1950, Nanterre, France), and mounted on Superfrost slides (Thermo Fisher 476 
Scientific, Villebonne-sur-Yvette, France). Slides were washed in phosphate buffered saline 477 
(PBS), 0.5% Triton X-100, and 1% bovine serum albumin (BSA) solution (Sigma, Saint-478 
Quentin Fallavier, France) and incubated overnight at 4°C with the primary antibodies anti–479 
Mrgprd (1:500, AMR-061, Alomone labs, Clinisciences, Nanterre, France) and anti-PGP9.5 480 
(1:500, AB86808, Abcam, Coger SAS, Paris, France). After washing, slides were incubated 481 
with the appropriate secondary antibody conjugated with Alexa Fluor® 488 or Alexa Fluor® 482 
555 (Thermo Fisher Scientific), washed, and mounted with ProLong Gold reagent containing 483 
DAPI (Molecular Probes). Images were acquired using Zeiss LSM-710 confocal microscopes 484 
(Carl Zeiss MicroImaging, Jena, Germany) with 20X objective in the inverted configuration. 485 
 486 
Single-cell qRT-PCR of retrogradely labelled mouse sensory neurons 487 
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Dorsal root ganglia neurons projecting to the colon were selectively labelled, individually 488 
harvested by pulled glass pipette. After RNA extraction, single-cell RT-qPCR for the presence 489 
of Mrgprd mRNA transcripts was performed as previously described (62). In brief, adult mice 490 
were subjected to laparotomy under anesthesia and 6-8 injections of Fast Blue (~ 0.2 L, 2 % 491 
in saline; Polysciences GmbH) were made into the wall of the distal colon. Five days post-492 
surgery, thoracolumbar (TL; T10-L1) DRG were collected and enzymatically dissociated (62). 493 
Individual cells were isolated by pulled glass pipette and collected into a preamplification 494 
mastermix containing 0.1 μL SUPERase-in (Ambion, TX, USA), 0.2 μL Superscript III Reverse 495 
Transcriptase/Platinum Taq mix (Invitrogen), 5 μL CellDirect 2x reaction buffer (Invitrogen), 496 
2.5 μL 0.2x primer/probe mix and 1.2 μL TE buffer (Applichem, GmbH) before thermal cycling 497 
(50 °C for 30 min, 95 °C for 2 min, then 21 cycles of (95 °C for 15 seconds, 60 °C for 4 min)). 498 
TaqMan qPCR assays for Mrgprd (TaqMan Assay ID: Mm01701850_s1) and Trpv1 499 
(Mm01246300_m1) were performed on diluted cDNA products (1:5 in TE buffer) using the 500 
following cycling protocol: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of (95°C 501 
for 15 seconds, 60°C for 1 minutes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 502 
acted as an internal positive control and sample of the bath solution was used as a no-template 503 
negative control, with all single-cell RT-PCR products expressing GAPDH, whilst bath control 504 
samples did not. The quantitative assessment of gene expression was determined by 505 
quantification of cycle (Cq) values lower than the threshold of 35 that were considered as 506 
positive. In total, 15 single cells per spinal region (TL) per mouse (n=3) were isolated, therefore 507 
the expression of mRNA transcripts was determined in 45 colonic sensory neurons.  508 
 509 
Immunohistochemistry of Fast Blue-labelled colonic sensory neurons from MrgprdEGFP 510 
tagged mice.  511 
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From thoracolumbar regions, DRG T13 were stained from 4 MrgprdEGFP mice retrogradely 512 
labelled with Fast Blue to the colon, as described above. A single T13 DRG was sectioned 513 
sequentially across 10 slides at 12 µm thickness. Therefore, on a given slide, the T13 DRG was 514 
sampled at 120 µm intervals for the full thickness of the DRG. In total 16 sections from 4 515 
animals were analysed, yielding 274 Fast Blue labelled cells. Slides were stained with chicken 516 
anti-GFP (1:1000; Abcam Ab13790) and rabbit anti-CGRP (1:10000, Sigma C8198) antisera. 517 
Secondary antibody used were goat anti-Chicken-488 (1:1000) and donkey anti-Rabbit-594 518 
(1:1000). Each probe (e.g. MrgprdEGFP and CGRP) per section has a background reading 519 
subtracted and was normalised between the maximum and minimum intensity cells. A threshold 520 
of mean + 3 times SD for the minimum intensity cells (from all 16 sections) was used to 521 
differentiate positive from negative cells. Positive cells were then manually confirmed. 522 
 523 
Ca2+ imaging of mouse sensory neurons 524 
Dorsal root ganglia of wild-type and Mrgprd deficient mice were rinsed in cold HBSS 525 
(Invitrogen), and enzymatically dissociated as described previously (63). Neurons were plated 526 
in 96 wells plate (fluorescence Greiner bio one, Domique Dutscher, Brumath, France) and 527 
cultured for 24 hours. In a first set of experiments, neurons were treated with 5-oxoETE (1, 5, 528 
25, 50 and 100 µM) or vehicle (HBSS). In a second set of experiments, neurons were incubated 529 
for 1 hour with 10 µg/mL of isolectin B4 from Griffonia simplicifolia conjugated to Alexa 530 
Fluor® 594 (ThermoFisher) in order to differentiate IB4-positive and -negative sensory 531 
neurons. Ca2+ flux was monitored by recording changing emission intensity of Fluo-4 532 
(Molecular probe) following treatment with 5-oxoETE (10 µM) or its vehicle.  In a third set of 533 
experiments, neurons were pre-incubated with pertussis toxin (PTX, 250 ng/mL) overnight or 534 
with the U73122 phospholipase C inhibitor (10 µM) 30 min, before treatment with 5-oxoETE 535 
(50 µM) or its vehicle.  536 
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 537 
Expression of shRNA directed against Mrgprd in sensory neurons 538 
Lentiviral particles were produced as previously described (64). Briefly, HEK293T/17 cells 539 
were cultured according to supplier’s recommendations (ATCC, USA). 1.7x107 cells were 540 
seeded into a 175 cm2 culture flask containing 30 mL of DMEM (Gibco, USA) and then 541 
incubated at 37°C 5% CO2. In the next day, cells were transfected with a mixture of structural 542 
(psPAX2 and pMD2.G; Addgene, Cambridge, MA, USA) and transfer vectors (shRNA 543 
Mrgprd-RFP-CB or the control shRNA-RFP-CB; OriGene Technologies, Rockville, USA), by 544 
using the transfection reagent GeneJuice (Millipore, USA). Cells were incubated overnight at 545 
37°C 5% CO2, then the medium was replaced by 18 mL of OptiMEM (Gibco, USA). Cell 546 
culture supernatants were harvested 48 h later, cleared by centrifugation and filtration with a 547 
0.45 m syringe filter. Neurons plated in 96 wells plate coated with poly-L-ornithine/laminin 548 
and cultivated in Neurobasal medium supplemented with B27 and L-glutamine were transduced 549 
with 50 μL of lentivirus supernatant. Three days later, a transduction efficiency of 35 % was 550 
achieved and calcium flux assay was performed in response to 5-oxoETE (10 µM), as described 551 
above. 552 
 553 
Ca2+ flux in CHO cells expressing Mrgprd  554 
Mouse Mrgprd-expression plasmid (OriGene Technologies, Rockville, USA) was transfected 555 
into CHO cells using GeneJuice Transfection Reagent (1 μg of plasmid for 3 μL of GeneJuice). 556 
The cells were incubated in Ham’s F12 Nutrient Mixture with 5% of FBS. G418 (Sigma) was 557 
used as the selection antibiotic. 50×103 cells/well in a 96 wells plate were incubated with fluo-558 
8 loading solution (Fluo-8-AM; Invitrogen) according to manufacturer’s instructions. The 559 
fluorescence was then measured at 530 nm on a microplate reader (NOVOstar; BMG Labtech) 560 
for 1 min. Five seconds after the beginning of calcium measures, 5-oxoETE (1, 10, 25, 50, 100 561 
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and 200 µM) or -alanine (Sigma-Aldrich; 1 mM) was added. Data were collected and analyzed 562 
with the NOVOstar software. 563 
 564 
Ca2+ imaging of human sensory neurons 565 
Experiments were conducted following the opinion number 14-164 of the institutional review 566 
board (IRB00003888) of French institute of medical research and health. Three human DRG 567 
T11 (thoracic position 11) were supplied through the national human tissue resource center 568 
from the national disease resource interchange (NDRI). DRG were received unfixed in DMEM 569 
at 4°C. DRG were dissected, minced in HBSS and incubated in Papain (27µg/mL) (Sigma, 570 
Saint Quentin Fallavier, France) for 20 min at 37°C. After a wash with L-15 Wash Buffer 571 
[Leibovitz’s L-15 Medium (Invitrogen), 10% FBS (Invitrogen)] and HBSS, DRG were 572 
incubated in HBSS containing 1 mg/mL of collagenase type IV (Worthington, Lakewood, NJ, 573 
USA) and 4 mg/mL of dispase II (Sigma). L-15 Wash buffer was added to neutralize enzymatic 574 
activities and the suspension was centrifuged at 1000 g for 5 min. The cycle of digestion was 575 
repeated 3 times 15 min. Neurons in the pellet were suspended in Neurobasal medium 576 
(Invitrogen) containing 2% B27, 2 mmol/L glutamine, 1% penicillin/streptomycin and 10 µM 577 
each of cytosine arabinoside, 5-Fluoro-2′-deoxyuridine (FUDR), Uridine (all from Sigma). The 578 
medium was changed every 3 days without cytosine arabinoside. Cells were plated in CC2 579 
LabTek II (Nunc, Domique Dutscher, Brumath, France) for calcium signalling assay as 580 
described above in response to 5-oxoETE (0.1, 1 and 10 µM) and immunochemistry. 581 
 582 
Immunofluorescence in human dorsal root ganglia 583 
Experiments were conducted following the opinion number 12-074 of the institutional review 584 
board (IRB00003888) of French institute of medical research and health. Two human DRG T11 585 
(thoracic position 11) were supplied through the national human tissue resource center from the 586 
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national disease resource interchange (NDRI). DRG were received unfixed and cryoprotected. 587 
DRG were cut into 20 µm sections on a cryostat (Leica CM1950, Nanterre, France), and 588 
mounted on Superfrost slides (Thermo Fisher Scientific, Villebonne-sur-Yvette, France). 589 
Cultured sensory neurons and slides were washed in phosphate buffered saline (PBS), 0.5% 590 
Triton X-100, and 1% bovine serum albumin (BSA) solution (Sigma, Saint-Quentin Fallavier, 591 
France) and incubated overnight at 4°C with the anti–Mrgprd (1:100, LS-A4123, LifeSpan 592 
Biosciences, Clinisciences, Nanterre, France) and anti-PGP9.5 (1:500, AB86808, Abcam). 593 
After washing, slides and cultured DRG were incubated with the appropriate secondary 594 
antibody conjugated with Alexa Fluor 488 or Alexa Fluor 555, washed, and mounted with 595 
ProLong Gold reagent containing DAPI (Molecular Probes). Images were acquired using Zeiss 596 
LSM-710 confocal microscopes (Carl Zeiss MicroImaging, Jena, Germany) with 20X objective 597 
in the inverted configuration. 598 
  599 
Statistics  600 
Data are presented as means ± standard error of the mean (SEM). Analyses were performed 601 
using GraphPad Prism 5.0 software (GraphPad, San Diego, CA). Comparisons between-groups 602 
were performed by Mann-Whitney test. Multiple comparisons within groups were performed 603 
by Kruskal-Wallis test, followed by Dunn’s post-test. Statistical significance was accepted at P 604 
< 0.05.  605 
 606 
Study approval 607 
The study protocol for biopsies collection was approved by the local Ethic Committee 608 
(64/2004/O/Sper and EM14/2006/O) and conducted in accordance with the Declaration of 609 
Helsinki. Patients and HC gave written informed consent. Fixed and fresh Human DRG were 610 
supplied through the national human tissue resource center from the national disease resource 611 
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interchange (NDRI, reference: DCEN1 001). Experiments on human DRG were conducted 612 
following the opinion number 14-164 of the institutional review board (IRB00003888) of 613 
French institute of medical research and health. Animal experiments were conducted following 614 
the European union council directive 2010/63/EU. Animal Care and ethic Committee of 615 
US006/CREFE (CEEA-122) approved the whole study protocol (permit No. MP/01/64/09/12). 616 
Experiments conducted at the University of Glasgow were approved by the University’s Ethical 617 
Review Process Applications Panel, and were performed in accordance with the European 618 
Community directive 86/609/EC and the United Kingdom Animals (Scientific Procedures) Act 619 
1986. 620 
 621 
Supplementary Materials 622 
Fig. S1: Concentration of PUFA metabolites in biopsies of IBS patients 623 
Fig. S2: Concentration of PUFA metabolites in biopsies of all IBS patients.  624 
Fig. S3: 5-oxoETE does not induce somatic or visceral inflammation in vivo. 625 
Fig. S4: Mrgprd immunoreactivity is observed in mouse colon 626 
Fig. S5: Mrgprd immunoreactivity is not observed in colon of Mrgprd deficient mice. 627 
 628 
  629 
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 Table 1:  Characteristics of patients from which biopsies were collected for PUFA metabolites 850 
quantification 851 
 Control IBS 
Number 14 50 
Age 49 (20-76) 43 (20-72) 
Sex ratio (F/M) 8/6 32/18 
Bowel movements:   
Diarrhea 0 20 
Constipation 0 20 
Mix 0 10 
 852 
 853 
Table 2: Percentage of fast-blue positive neurons expressing Mrgprd, CGRP or both per 854 
Mrgprd-GFP mouse DRG T13 855 
Animal Mrgprd+ CGRP+ 
Mrgprd+ & 
CGRP+ 
A 9 / 75 (12.0%) 54 / 75 (72.0%) 0 / 75 (0.0%) 
B 2 / 38 (5.3%) 24 / 38 (63.2%) 0 / 38 (0.0%) 
C 10 / 101 (9.9%) 64 / 101 (63.4%) 1 / 101 (1.0%) 
D 1 / 60 (1.7%) 46 / 60 (76.7%) 0 / 60 (0.0%) 
Total (mean ± SD) 7.2 ± 4.6 % 68.8 ± 6.7 % 0.3 ± 0.5 % 
 856 
 857 
  858 
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 859 
Fig.1: Quantification of PUFA metabolites in mucosa of IBS patients. A Heat-map of PUFA 860 
metabolites quantified by liquid chromatography-tandem mass spectrometry. Data are shown 861 
in a matrix format: each row represents a single PUFA metabolite, and each column represents 862 
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a subgroup of patients. Each color patch represents the normalized quantity of PUFA 863 
metabolites (row) in a subgroup of patients (column), with a continuum of quantity from bright 864 
green (lowest) to bright red (highest). The pattern and length of the branches in the dendrograms 865 
reflect the relatedness of the PUFA metabolites. The dashed red line is the dendrogram distance 866 
used to cluster PUFA metabolites. B 5-oxoETE quantified by liquid chromatography-tandem 867 
mass spectrometry in mucosa of healthy control (white circle) and IBS (black circle). Data are 868 
expressed in pg/mg protein and represented as mean ± SEM of 10 to 20 biopsies per group. 869 
Statistical analysis was performed using Kruskal-Wallis analysis of variance and subsequent 870 
Dunn’s post hoc test. *** p< 0.001, significantly different from healthy control group. 871 
  872 
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 873 
Fig.2: 5-oxoETE induces somatic and visceral hypersensitivity in vivo. Mice were 874 
subcutaneously injected with either HBSS (white circle) or 5-oxoETE (black circle) into hind 875 
footpads. A Somatic pain monitored using the von Frey test at different times (15 and 30 min, 876 
HBSS 5-oxoETE (100 μM)
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1, 2 and 6 hours) following 5-oxoETE (10 µM) injection; n=3 independent experiments of 5 877 
mice per groups. B Von Frey test performed 30 min after injection of 5-oxoETE at different 878 
concentrations (0.1, 1, 10 or 100 µM); n=2 experiments of 6 mice per group. Data are expressed 879 
as mean ± SEM. C Mouse paw tissue samples stained with H&E 6 h after administration of 880 
HBSS (left panel) or 5-oxoETE (100 µM) (right panel). D Visceromotor response (VMR) to 881 
increasing pressures of colorectal distension before and 30 min after intracolonic administration 882 
of 5-oxoETE (10µM; black bars) or vehicle (40% ethanol; white bars); n=2 experiments of 10 883 
mice per group. Data are expressed as mean ± SEM relative to the baseline recorded before 884 
treatment. E Colon tissue samples stained with H&E from 40% ethanol treated-mice (1 hour) 885 
(upper panel) or 5-oxoETE-treated mice (10 µM; 1 hour) (lower panel). Statistical analysis was 886 
performed using Kruskal-Wallis analysis of variance and subsequent Dunn’s post hoc test. ** 887 
p<0.01, *** p<0.001, significantly different from control mice.  888 
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 890 
Fig.3: 5-oxoETE induces lumbar splanchnic nerve firing. A Example of multi-unit recording 891 
showing lumbar splanchnic (i.e. colon-innervating) nerve response to ring application (7 min) 892 
of 5-oxoETE in mouse serosal afferents. Arrows indicate application and removal of 5-oxoETE. 893 
B Mean change in firing/second in serosal and mesenteric receptive fields compared with 894 
vehicle response of Krebs buffer. Statistical analysis was performed using Mann-Whitney t-895 
test. ** p<0.01, significantly different from vehicle. C Proportion of responses in lumbar 896 
splanchnic afferents to application of 5-oxoETE.  897 
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 898 
Fig.4: 5-oxoETE induces an increase in [Ca2+] in sensory neurons via a GPCR. A 899 
Representative trace of Ca2+ flux experiments in sensory neurons performed without Ca2+/Mg2+ 900 
in the extracellular medium and exposed to 5-oxoETE (50 µM) or its vehicle (HBSS). B Ca2+  901 
flux in mouse sensory neurons exposed to increasing amounts of 5-oxoETE (black circle) or 902 
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vehicle (HBSS; white circle); n=7 independent experiments of 3 wells per condition and 60 to 903 
80 neurons per well. C Amplitude of [Ca2+]i (F/F; left panel) in human sensory neurons and 904 
percentage of responding neurons (right panel) exposed to increasing amounts of 5-oxoETE 905 
(black bar) or vehicle (HBSS; white bar); n=3 independent experiments of 3 wells per condition 906 
and 20-53 neurons per well. D Percentage of isolectin B4-positive (IB4+) and -negative (IB4-) 907 
mouse sensory neurons responding to 10 µM of 5-oxoETE; n=3 independent experiments of 3 908 
wells per condition and 60 to 80 neurons per well. E Effects of 30 min incubation with PLC 909 
inhibitor (U73122; 10 μM) or overnight incubation with pertussis toxin (PTX; 250 ng/ml) on 910 
5-oxoETE-induced Ca2+ mobilization in mouse sensory neurons; n=5 independent experiments 911 
of 3 wells per condition and 60 to 80 neurons per well. Statistical analysis was performed using 912 
Kruskal-Wallis analysis of variance and subsequent Dunn’s post hoc test. Data are mean ± 913 
SEM. * p<0.05, ** p<0.01, *** p<0.001 significantly different from HBSS group. 914 
40 
 
 915 
Fig.5: Expression of Mrgprd in sensory neurons. A Expression of Mrgprd (in red) and trpv1 916 
(in blue) mRNA transcripts by single-cell qRT-PCR (middle panel) of retrogradely labelled 917 
mouse colonic sensory neurons (left panel). Pie charts representation of the expression (dark 918 
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color) or not (light color) of Mrgprd and Trpv1 mRNA in FB positive neurons (right panel), 919 
each segment represents a single colonic sensory neuron. (B) Representative images of GFP 920 
(green), CGRP- (red) immunoreactivity and FB labelling (blue) in a T13 DRG  from 921 
MrgprdEGFP mouse where FB was injected into the colon (scale bar = 50 µm). Expression of 922 
Mrgprd in whole human dorsal root ganglia (C) and in primary culture of human sensory 923 
neurons (D); human whole DRG T11 (C, scale bar = 10 µm) or primary culture of sensory 924 
neurons (D, scale bar = 10 µm).   925 
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 927 
Fig.6: Mrgprd expression is required for the intracellular calcium mobilization and 928 
hypersensitivity induced by 5-oxoETE. A Left panel, representative picture of sensory 929 
neurons transfected with shRNA (in red) containing the calcium probe Fluo4 (in green); right 930 
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panel, percentage of shRNA directed against Mrgprd or control positive sensory neurons 931 
responding to 10 µM of 5-oxoETE; n=6 independent experiments of 3 wells per conditions and 932 
10 to 32 analyzed neurons per well. B Percentage of responding neurons (right panel) and 933 
amplitude of intracellular calcium mobilization (F/F; left panel) in mouse sensory neurons 934 
from Mrgprd deficient mice exposed to vehicle (HBSS; white bar), 5-oxoETE (10 µM, black 935 
bar) or to a mix of GPCR agonist (GPCR Mix: bradykinin, serotonin and histamine, 10 µM 936 
each; gray bar); n=4 independent experiments of 3 wells per condition and 20-50 neurons per 937 
well.  C Effects of 5-oxoETE (1–200 μM) and -Alanine (positive control), 1 mM) on the 938 
amplitude (F/F) of calcium mobilization in HEK cells transiently expressing Mrgprd or vector 939 
control; n=8 independent experiments of 3 wells per condition. D Visceromotor response 940 
(VMR) in Mrgprd deficient mice to increasing pressures of colorectal distension before 941 
(baseline; white circle) and 30 min after intracolonic administration of 5-oxoETE (10 µM; black 942 
circle); n=2 experiments of 7 mice. Data are mean ± SEM. Statistical analysis was performed 943 
using Kruskal-Wallis analysis of variance and subsequent Dunn’s post hoc test. ** p<0.01 944 
significantly different from control shRNA/HBSS group (A); **p<0.01 significantly different 945 
from HBSS group (B); * p<0.05; **p<0.01; *** p<0.001 significantly different from the 946 
corresponding CHO empty vector group (C). 947 
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